Gilead Sciences (GILD) Tops Q4 EPS by 1c; Authorizes $5B Buyback Plan; Receives 'Refuse to File' Notification from FDA
Tweet Send to a Friend
Gilead Sciences Inc. (NASDAQ: GILD) reported Q4 EPS of $0.95, $0.01 better than the analyst estimate of $0.94. Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
